IP Library Granted Patent US 8,263,101
Granted Patent B2
US 8,263,101 · App. 13/217,566 · Granted Sep 11, 2012

Passive methods for anti-microbial biological meshes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,101
App. No.
13/217,566
Granted
Sep 11, 2012
Kind
B2
Abstract

Tissue matrices having anti-microbial properties are provided. In certain embodiments, the tissue matrices include cationic anti-microbial agents that form a stable bond with the tissue matrices without adversely affecting the biologic properties of the tissue matrices.

Claims (31)

1. An anti-microbial tissue matrix prepared by:

selecting a collagen-based tissue; and

contacting the tissue with an aqueous solution containing a cationic anti-microbial agent, wherein the agent is stably bound to a tissue matrix within the collagen-based tissue by passive adsorption in the aqueous solution, and wherein the tissue has been exposed to E-beam radiation.

2. The anti-microbial tissue matrix of claim 1 , wherein the aqueous solution is non-denaturing.

3. The anti-microbial tissue matrix of claim 1 , wherein the collagen-based tissue is an acellular tissue.

4. The anti-microbial tissue matrix of claim 1 , wherein the collagen-based tissue comprises an acellular dermal tissue.

5. The anti-microbial tissue matrix of claim 1 , wherein the collagen-based tissue comprises an acellular porcine dermal tissue.

6. The anti-microbial tissue matrix of claim 1 , wherein the anti-microbial compound comprises benzethonium chloride, chlorhexidine, benzalkonium chloride, silver nitrate, poly-hexa-methylene biguanide hydrochloride, cationic peptides, chitosan, or quaternary ammonium compounds.

7. The anti-microbial tissue matrix of claim 1 , wherein the collagen-based tissue is not cross-linked or denatured during binding of the anti-microbial agent.

8. The anti-microbial tissue matrix of claim 1 , wherein the anti-microbial agent is not covalently modified by binding to the collagen-based tissue.

9. The anti-microbial tissue matrix of claim 1 , wherein the tissue matrix retains anti-microbial properties for at least two weeks after binding the antimicrobial agent.

10. The anti-microbial tissue matrix of claim 1 , prepared by contacting the collagen-based tissue with the aqueous solution containing the cationic anti-microbial agent for at least four hours at room temperature.

11. The anti-microbial tissue matrix of claim 1 , wherein the antimicrobial agent remains bound to the tissue matrix when the tissue matrix is placed in a non-denaturing aqueous solution.

12. The anti-microbial tissue matrix of claim 1 , wherein the antimicrobial agent remains bound to the tissue matrix when the tissue matrix is placed in PBS.

13. The anti-microbial tissue matrix of claim 1 , wherein the bound anti-microbial agent retains greater than 95% of its activity when the tissue matrix is placed in PBS for two weeks at room temperature.

14. The anti-microbial tissue matrix of claim 1 , wherein the bound anti-microbial agent retains greater than 75% of its activity when the tissue matrix is placed in PBS for two weeks at room temperature.

15. An anti-microbial tissue matrix comprising:

a collagen-based tissue; and

at least one cationic anti-microbial agent that is stably bound to the collagen-based tissue by passive adsorption in an aqueous solution, and wherein the collagen-based tissue has been exposed to E-beam radiation.

16. The anti-microbial tissue matrix of claim 15 , wherein binding of the anti-microbial agent to the collagen-based tissue occurs in a non-denaturing aqueous solution.

17. The anti-microbial tissue matrix of claim 15 , wherein the collagen-based tissue comprises an acellular dermal tissue.

18. The anti-microbial tissue matrix of claim 15 , wherein the collagen-based tissue comprises an acellular porcine dermal tissue.

19. The anti-microbial tissue matrix of claim 15 , wherein the anti-microbial compound comprises at least one of benzethonium chloride, chlorhexidine, benzalkonium chloride, silver nitrate, poly-hexa-methylene biguanide hydrochloride, cationic peptides, chitosan, or quaternary ammonium compounds.

20. The anti-microbial tissue matrix of claim 15 , wherein the collagen-based tissue is not cross-linked or denatured during binding of the anti-microbial agent.

21. The anti-microbial tissue matrix of claim 15 , wherein the anti-microbial agent is not covalently modified by binding to the collagen-based tissue.

22. The anti-microbial tissue matrix of claim 15 , wherein the tissue matrix retains anti-microbial properties for at least two weeks after binding the anti-microbial agent.

23. The anti-microbial tissue matrix of claim 15 , prepared by contacting the collagen-based tissue with the aqueous solution containing the cationic anti-microbial agent for at least four hours at room temperature.

24. The anti-microbial tissue matrix of claim 15 , wherein the antimicrobial agent remains bound to the tissue matrix when the tissue matrix is placed in a non-denaturing aqueous solution.

25. The anti-microbial tissue matrix of claim 15 , wherein the antimicrobial agent remains bound to the tissue matrix when the tissue matrix is placed in PBS.

26. The anti-microbial tissue matrix of claim 15 , wherein the bound anti-microbial agent retains greater than 95% of its activity when the tissue matrix is placed in PBS for two weeks at room temperature.

27. The anti-microbial tissue matrix of claim 15 , wherein the bound anti-microbial agent retains greater than 75% of its activity when the tissue matrix is placed in PBS for two weeks at room temperature.

Assignments (7)
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2015
From: OWENS, RICK T.; LIU, MIKE; MAO, YONG
To: LIFECELL CORPORATION
Reel/Frame 034776/0833 →